# To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects

> **NCT07054970** · PHASE1 · COMPLETED · sponsor: **Celltrion** · enrollment: 172 (actual)

## Conditions studied

- Healthy Male Subjects

## Interventions

- **BIOLOGICAL:** CT-P55
- **BIOLOGICAL:** US-licensed Cosentyx
- **BIOLOGICAL:** EU-approved Cosentyx

## Key facts

- **NCT ID:** NCT07054970
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-12
- **Primary completion:** 2024-08-29
- **Final completion:** 2024-09-06
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07054970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07054970, "To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07054970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*